NCT00066638View on ClinicalTrials.gov

FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

May 31, 2007

Study Completion Date

March 31, 2011

Conditions
DS Stage II Plasma Cell MyelomaDS Stage III Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Interventions
DRUG

Romidepsin

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

10467-2490

Montefiore Medical Center - Moses Campus, The Bronx

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00066638 - FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter